Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

AbstractObjectivesAs of December, 1st, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage.The angiotensin converting enzyme 2 (ACE2) serves as a receptor for SARS-CoV-2. Interaction between ACE2 and SARS-CoV2 spike protein seems to alter the function of ACE2, a key player in the renin-angiotensin system (RAS). The clinical picture of COVID-19 includes acute respiratory distress syndrome (ARDS), cardiomyopathy, multiorgan dysfunction and shock, all of which might result from an imbalance of the RAS. We propose that RAS balance could be restored in COVID-19 patients through MasR activation downstream of ACE2 activity, with 20-hydroxyecdysone (BIO101) a non-peptidic Mas receptor (MasR) activator. Indeed, MasR activation by 20-hydroxyecdysone harbours anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. BIO101, a 97% pharmace...
Source: Trials - Category: Research Source Type: clinical trials

Related Links:

Prof Dame Sarah Gilbert says this will not be the last time a virus threatens our lives and our livelihoodsCoronavirus – latest updatesSee all our coronavirus coverageThe coronavirus pandemic that has so far killed more than 5 million people worldwide is far from over and the next one could be even more lethal, the creator of the Oxford/AstraZeneca vaccine has said.As fears grow over the threat posed by the highly mutated Omicron variant, detected in more than 30 countries,Prof Dame Sarah Gilbert cautioned that while it was increasingly obvious that “this pandemic is not done with us”, the next one could ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus UK news World news Science Infectious diseases Source Type: news
An Italian healthcare worker was caught trying to fraudulently receive a Covid-19 vaccine in a silicone arm.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Source Type: news
A small study in Boston looked at mixing and matching with the third shot.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Johnson & Pfizer Inc BioNTech SE Source Type: news
For the first time in two months, the US is averaging more than 100,000 new Covid-19 cases each day, shortly after millions of Americans traveled for the Thanksgiving holiday.
Source: Reuters: Health - Category: Consumer Health News Source Type: news
The Omicron variant of the coronavirus has spread to about one-third of U.S. states, but the Delta version remains the majority of COVID-19 infections as cases rise nationwide, U.S. health... #healthofficials
Source: Reuters: Health - Category: Consumer Health News Source Type: news
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match)....
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Two hippos at a zoo in Antwerp, Belgium, have tested positive for Covid-19, in what is believed to be the first such infection reported in the species. #antwerp
Source: Reuters: Health - Category: Consumer Health News Source Type: news
Experts said it is likely that there is already community spread of the variant in the United States.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus Omicron Variant Coronavirus (2019-nCoV) Vaccination and Immunization Collins, Francis S Fauci, Anthony S Van Kerkhove, Maria Walensky, Rochelle United States South Africa Disease Rates Source Type: news
U.S. health officials say that while the omicron variant of the coronavirus is rapidly spreading in the country, early indications suggest it may be less dangerous than delta, which continues to... #fauci #healthofficials #hospitalizations
Source: Reuters: Health - Category: Consumer Health News Source Type: news
At least 10 passengers and crew members are infected with COVID-19.
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
More News: Amenorrhea | Belgium Health | Bilirubin | Brazil Health | Breastfed | Cardiology | Cardiomyopathy | Complementary Medicine | Coronavirus | COVID-19 | Diabetes | Dialysis | Eating Disorders & Weight Management | Endocrinology | France Health | Heart | Heart Disease | Herbs | Hospitals | Hypertension | International Medicine & Public Health | Legislation | Liver | Men | Menopause | Myocarditis | Obesity | Pericarditis | Pneumonia | Pregnancy | Reproduction Medicine | Research | Respiratory Medicine | SARS | Statistics | Study | Urology & Nephrology | Vasectomy | Websites